MarketCapExport financials
U.S. Physical Therapy (USPH)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
U.S. Physical Therapy Financial Ratios 2025-2008 | USPH
Brief overview of U.S. Physical Therapy's valuation and returns
Ratios are assessed across five available annual reports in the 2021–2025 interval.
Key multiples at the end of the period are P/E 31.67x (median 38.23x), EV/EBITDA 15.15x (median 19.2x), P/S 1.61x (median 2.39x). The current ratio basket stands about 21.1% below the five-year comparison base. Earnings and risk trends should explain the discount.
Earnings yield calculated as 1/P/E is about 3.2%, showing current profit per unit of share price.
Returns on assets and capital are represented by ROE 8.3%, ROA 3.3%, ROCE 18.2%. Profitability sends a weak positive signal and leaves the business sensitive to cost or demand pressure.
Current PEG of 3.16x points to a premium over forecast earnings momentum.
The cash conversion cycle remains near its former level at 24.1 days after 29.5 days.
Overall assessment
U.S. Physical Therapy trades below its own history, but weak profitability may explain the discount. Low multiples alone do not prove undervaluation.
Annual Financial Ratios U.S. Physical Therapy
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31.7 | 38.2 | 53.2 | 41.1 | 30.5 | 43.3 | 36.9 | 38.6 | 43.2 | 41.8 | 28.5 | 22.7 | 30.6 | 16.4 | 11.5 | 12.3 | 14.1 | - | |
P/S |
1.6 | 1.8 | 2.5 | 2.4 | 2.5 | 3.6 | 3.1 | 3.0 | 2.3 | 2.4 | 1.9 | 1.6 | 1.5 | 1.2 | 1.0 | - | - | - |
EPS |
1.4 | 1.8 | 1.3 | 2.2 | 2.4 | 2.5 | 2.5 | 1.3 | 1.8 | 1.6 | 1.8 | 1.6 | 1.1 | 1.5 | 1.8 | 1.3 | 1.0 | - |
EV (Enterprise Value) |
1.65 B | 1.57 B | 1.69 B | 1.66 B | 1.51 B | 1.68 B | 1.77 B | 1.55 B | 1.15 B | 1 B | 705 M | 537 M | 450 M | 319 M | 273 M | 207 M | 160 M | -10.1 M |
EBITDA per Share |
7.19 | 5.42 | 4.67 | 5.51 | 6.38 | 4.9 | 6.08 | 5.53 | 5.13 | 4.66 | 4.46 | 4.3 | 3.68 | 3.65 | 3.5 | 3.34 | 2.92 | - |
EV/EBITDA |
15.1 | 19.2 | 25.6 | 23.2 | 18.4 | 26.6 | 19.4 | 19.4 | 15.5 | 15.3 | 12.1 | 9.4 | 9.4 | 7.0 | 6.2 | 5.3 | 4.7 | - |
PEG |
3.16 | -96.19 | -32.46 | 13.73 | 3.96 | 16.75 | 0.42 | -1.51 | 5.9 | -5.7 | 7.69 | 0.37 | -1.0 | -1.12 | 0.35 | - | - | - |
P/B |
1.6 | 1.6 | 2.3 | 2.7 | 2.7 | 3.7 | 6.1 | 6.2 | 4.7 | 4.6 | 3.9 | 3.2 | 3.0 | 2.5 | 2.3 | 1.6 | - | - |
P/CF |
16.7 | 16.0 | 18.3 | 22.6 | 16.3 | 15.2 | 28.2 | 20.4 | 19.5 | 20.1 | 18.1 | 11.8 | 9.7 | 8.4 | 8.2 | 6.3 | 5.4 | - |
ROE % |
8.31 | 6.43 | 5.93 | 10.18 | 13.81 | 12.74 | 16.67 | 16.15 | 10.86 | 10.96 | 13.69 | 14.26 | 9.92 | 15.29 | 19.59 | 15.05 | 12.76 | - |
ROA % |
3.29 | 2.69 | 2.83 | 3.75 | 5.45 | 5.92 | 7.14 | 7.87 | 5.31 | 5.85 | 7.96 | 8.53 | 5.68 | 10.44 | 12.85 | 11.11 | - | - |
ROCE % |
11.24 | 8.07 | 7.03 | 9.41 | 13.88 | 14.28 | 13.48 | 15.03 | 14.42 | 15.17 | 18.13 | 20.89 | 19.29 | 24.33 | 24.45 | 29.06 | 30.63 | - |
Current Ratio |
2.8 | 2.9 | 2.9 | 2.3 | 2.5 | 3.2 | 1.4 | 1.9 | 1.9 | 2.7 | 3.2 | 2.2 | 2.1 | 2.8 | 2.8 | 5.8 | - | - |
DSO |
28.8 | 30.1 | 31.3 | 32.4 | 32.5 | 38.0 | 42.4 | 41.4 | 44.4 | 42.5 | 42.5 | 41.2 | 45.2 | 40.1 | 46.1 | - | - | - |
DPO |
4.7 | 4.5 | 3.7 | 3.8 | 3.0 | 3.0 | 2.5 | 2.1 | 2.4 | 2.2 | 2.4 | 2.8 | 3.2 | 3.3 | 3.8 | 2.0 | - | - |
Operating Cycle |
- | - | - | - | - | - | 42.4 | 41.4 | 44.4 | 42.5 | 42.5 | 41.2 | 45.2 | 40.1 | 46.1 | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | 40.0 | 39.3 | 42.0 | 40.3 | 40.2 | 38.3 | 42.0 | 36.7 | 42.3 | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios U.S. Physical Therapy
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-1.04 | 0.25 | -0.12 | -0.43000000000000016 | 0.48 | 0.58 | 0.8 | 0.52 | 0.39 | 0.47 | 0.46 | -0.43999999999999995 | 0.51 | 0.64 | 0.58 | -0.020000000000000018 | 0.72 | 0.87 | 0.67 | 0.7200000000000002 | 0.66 | 0.82 | 0.21 | 0.6799999999999999 | 0.61 | 0.99 | 0.2 | 0.55 | 0.66 | 0.85 | 0.39 | 0.43 | 0.13 | 0.48 | 0.27 | 0.57 | 0.41 | 0.39 | 0.38 | 0.42 | 0.38 | 0.48 | 0.36 | 0.38 | 0.44 | 0.51 | 0.33 | 0.41 | 0.43 | 0.52 | 0.27 | 0.32 | 0.38 | 0.42 | 0.32 | 0.35 | 0.39 | 0.41 | 0.37 | 0.7 | 0.35 | 0.42 | 0.32 |
EBITDA per Share |
1.88 | 1.65 | 1.02 | -6.18 K | 1.88 | 1.85 | 1.5 | 2.53 | 1 | 1.18 | 1.13 | -2.14 | 1.18 | 1.59 | 1.44 | 1.42 | 1.26 | 1.66 | 1.33 | -0.68 | 1.39 | 1.79 | 1.23 | 3.18 | 1.62 | 0.87 | 0.38 | 1.26 | 1.38 | 1.62 | 1.27 | 1.22 | 1.28 | 1.39 | 1.09 | 1.15 | 1.08 | 1.3 | 1.03 | 0.94 | 1 | 1.24 | 0.96 | 1.06 | 0.99 | 1.12 | 0.78 | 0.92 | 0.97 | 1.18 | 0.8 | 0.79 | 0.84 | 0.93 | 0.73 | 0.7 | 0.8 | 0.91 | 0.83 | 0.27 | 0.84 | 1.15 | 0.85 |
ROE % |
11.07 | 10.47 | 10.68 | 11.65 | 12.27 | 10.80 | 9.68 | 9.40 | 6.57 | 7.03 | 7.65 | 8.82 | 10.14 | 11.69 | 13.60 | 13.98 | 17.79 | 18.62 | 19.82 | 20.14 | 21.99 | 23.06 | 22.68 | 19.77 | 18.03 | 17.61 | 20.44 | 24.65 | 25.99 | 26.05 | 23.70 | 22.92 | 20.72 | 18.45 | 15.49 | 13.80 | 10.27 | 10.29 | 11.25 | 12.39 | 13.93 | 14.76 | 15.41 | 14.95 | 16.06 | 16.47 | 17.33 | 17.61 | 17.21 | 14.20 | 13.48 | 13.40 | 14.94 | 18.01 | 18.52 | 19.92 | 23.89 | 24.07 | 25.19 | 23.27 | 4.79 | 6.64 | 3.50 |
ROA % |
3.97 | 4.08 | 4.39 | 4.87 | 5.18 | 4.66 | 4.31 | 4.31 | 3.11 | 3.38 | 3.72 | 3.90 | 4.42 | 4.80 | 5.23 | 5.48 | 7.01 | 7.65 | 8.07 | 8.09 | 9.29 | 9.79 | 9.98 | 8.96 | 7.73 | 7.32 | 8.33 | 10.13 | 11.31 | 11.59 | 11.07 | 11.11 | 10.04 | 9.04 | 7.56 | 6.71 | 5.01 | 5.24 | 5.97 | 6.66 | 7.55 | 8.04 | 8.49 | 8.39 | 9.22 | 9.89 | 11.08 | 11.71 | 11.39 | 9.66 | 9.79 | 10.19 | 11.90 | 14.35 | 14.59 | 15.56 | 18.35 | 18.21 | 19.10 | 17.25 | 3.57 | 5.18 | 2.29 |
ROCE % |
9.41 | 9.54 | 9.99 | 10.92 | 11.26 | 9.87 | 8.87 | 8.47 | 5.62 | 5.96 | 6.51 | 7.23 | 8.69 | 9.19 | 10.09 | 10.23 | 12.33 | 13.85 | 15.76 | 16.93 | 18.64 | 20.33 | 17.68 | 14.53 | 13.81 | 12.63 | 15.21 | 19.15 | 20.47 | 21.36 | 21.98 | 22.05 | 21.56 | 19.58 | 17.77 | 16.28 | 14.59 | 14.95 | 15.58 | 15.82 | 16.89 | 17.27 | 17.42 | 17.26 | 18.25 | 19.13 | 20.68 | 21.75 | 21.48 | 22.39 | 22.53 | 23.10 | 23.29 | 23.37 | 23.67 | 24.92 | 21.76 | 21.37 | 22.60 | 24.29 | 5.75 | 8.23 | 8.11 |
Current Ratio |
2.5 | 2.6 | 2.7 | 2.8 | 2.9 | 2.9 | 2.8 | 2.9 | 2.9 | 2.9 | 3.0 | 2.9 | 2.9 | 2.9 | 2.3 | 2.3 | 2.4 | 2.4 | 2.5 | 2.5 | 3.1 | 3.9 | 4.1 | 3.2 | 3.4 | 3.0 | 2.3 | 3.5 | 3.0 | 2.9 | 3.2 | 4.8 | 4.0 | 4.0 | 4.1 | 3.8 | 2.1 | 2.0 | 2.0 | 2.2 | 2.2 | 2.2 | 2.1 | 2.3 | 2.3 | 2.3 | 2.3 | 3.5 | 3.2 | 3.2 | 3.2 | 3.2 | 5.5 | 5.2 | 4.8 | 4.6 | 5.1 | 4.5 | 4.3 | 3.9 | 3.9 | 4.5 | 3.9 |
DSO |
12.9 | 12.0 | 11.9 | 10.8 | 11.8 | 12.4 | 13.1 | 11.8 | 11.3 | 11.9 | 11.6 | 10.7 | 10.7 | 10.4 | 10.6 | 11.6 | 12.4 | 12.1 | 11.9 | 9.2 | 6.9 | 6.3 | 7.2 | 7.3 | 8.3 | 11.8 | 8.7 | 7.6 | 8.2 | 6.5 | 5.5 | 6.4 | 7.3 | 6.0 | 5.1 | 5.3 | 5.6 | 5.3 | 4.2 | 2.5 | 2.4 | 2.4 | 2.5 | 2.3 | 1.8 | 1.5 | 1.7 | 2.0 | 2.2 | 2.1 | 2.3 | 2.5 | 2.6 | 2.5 | 2.6 | 1.2 | - | - | - | - | - | - | - |
DPO |
4.3 | 5.0 | 4.9 | 5.1 | 4.5 | 4.1 | 4.9 | 5.1 | 4.8 | 4.2 | 4.3 | 4.2 | 4.2 | 4.2 | 4.0 | 4.3 | 4.6 | 4.0 | 4.0 | 2.9 | 2.1 | 2.5 | 2.4 | 1.7 | 2.3 | 5.0 | 3.6 | 3.5 | 3.6 | 2.8 | 2.7 | 2.8 | 2.7 | 2.4 | 2.9 | 2.9 | 2.5 | 2.8 | 3.0 | 3.4 | 3.5 | 3.6 | 3.7 | 3.2 | 3.0 | 3.9 | 4.3 | 3.9 | 4.1 | 3.7 | 3.8 | 3.8 | 3.3 | 3.7 | 4.4 | 4.6 | 4.2 | 3.9 | 4.4 | 5.2 | 4.7 | 4.9 | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company U.S. Physical Therapy, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Russia
Germany
Britain
China
